ASEAN and China Biosimilars Market by Molecule Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibody, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, and Peptide), and Application (Blood Disorder, Oncology Disease, Chronic & Autoimmune Disease, Growth Hormone Deficiency, and Others): Opportunity Analysis and Industry Forecast, 2017 - 2025
- ALL2809957
- 130 Pages
- November 2018
- Pharmaceuticals
ASEAN and China Biosimilars Market Overview:
The ASEAN and China biosimilars market was valued at $687.6 million in 2017 and is expected to reach $5,506.2 million by 2025 with a CAGR of 29.7% during the forecast period. Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that are anticipated to expire in future. The development and validation of biosimilars with reference biologics is a crucial part of the overall process. The key driving factor for biosimilars is their implied ability of providing more cost-effective treatment than branded biologics.
Key players operating in the pharmaceuticals industry are largely investing in the development of biosimilars that can be applied for the treatment of several chronic medical conditions. Biosimilars have the potential to offer up to 30% cost reduction as compared to branded biologics. This is attributed to the compact validation pathways that reduce the additional cost of clinical trials, which further assist manufacturers to achieve scale economies. The key contributing factor to the growth in demand for biosimilars across the ASEAN and Chinese market is the patent expiration of most of the blockbuster drugs in the past few years. However, the biosimilars industry is witnessing issues pertaining to achieving product efficiency while maintaining the required production capacity. This plays a pivotal role in the biosimilars industry considering the large population of ASEAN countries along with China. Progress in improving the product efficiency and quantity is expected to open new avenues for the expansion of the biosimilars market across ASEAN and China.
The ASEAN and China biosimilars market is segmented into molecule type, application, and region. Based on molecule type, the market is divided into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and peptide. Based on application, the market is classified into blood disorders, oncology diseases, chronic and autoimmune diseases, growth hormone deficiency, and others. Further, the chronic and autoimmune diseases segment is sub-categorized into diabetes, rheumatoid arthritis (RA), glaucoma, and others. Based on region, the market is analyzed across China and ASEAN region.
Key Benefits ASEAN and China Biosimilars Market:
- The study provides an in-depth analysis of the ASEAN and China biosimilars market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- A qualitative analysis of the driving factors and opportunities help analyze the competitive scenario of the market.
- Porter’s five forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
ASEAN and China Biosimilars Key Market Segments:
By Molecule Type
- Human Growth Hormone
- Erythropoietin
- Monoclonal Antibody
- Insulin
- Interferon
- Granulocyte-Colony Stimulating Factor
- Peptide
By Application
- Blood Disorders
- Oncology Diseases
- Chronic and Autoimmune Diseases
- Rheumatoid Arthritis (RA)
- Diabetes
- Glaucoma
- Others
- Growth Hormone Deficiency
- Others
By Region
- China
- ASEAN Region
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Vietnam
- Rest of ASEAN Countries
Key Market Players
- 3SBIO Inc.
- Qilu Pharmaceutical
- Novartis International AG (Sandoz International GmbH)
- Pfizer Inc. (Hospira)
- STADA Arzneimittel
- Beijing SL Pharmaceutical Co., Ltd.
- Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
- Amgen Inc.
- AstraZeneca Plc
- Teva Pharmaceutical Industries Ltd.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Asean biosimilars market size and forecast
3.5. China biosimilars market size and forecast
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Various blockbusters going off patent
3.6.1.2. High prevalence of chronic diseases among ageing population
3.6.1.3. Lower cost of biosimilars drugs than original biologics
3.6.2. Restraints
3.6.2.1. High initial investment in research and development
3.6.2.2. Medical efficacy and patient safety
3.6.3. Opportunity
3.6.3.1. Emergence of bio-better drugs
CHAPTER 4: ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Human growth hormone
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.3. Erythropoietin
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.4. Monoclonal antibodies
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.5. Insulin
4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast
4.6. Interferon
4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast
4.7. Granulocyte-Colony Stimulating Factor
4.7.1. Key market trends and growth opportunities
4.7.2. Market size and forecast
4.8. Peptide
4.8.1. Key market trends and growth opportunities
4.8.2. Market size and forecast
CHAPTER 5: ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Blood Disorders
5.2.1. Market size and forecast
5.3. Oncology Diseases
5.3.1. Market size and forecast
5.4. Chronic and Autoimmune Diseases
5.4.1. Market size and forecast
5.4.2. Rheumatoid Arthritis (RA)
5.4.2.1. Market size and forecast
5.4.3. Diabetes
5.4.3.1. Market size and forecast
5.4.4. Glaucoma
5.4.4.1. Market size and forecast
5.4.5. Others
5.4.5.1. Market size and forecast
5.5. Growth hormone deficiency
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast
CHAPTER 6: COMPANY PROFILES
6.1. 3SBIO INC.
6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance
6.1.6. Key strategic moves and developments
6.2. Qilu Pharmaceutical
6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments
6.3. Novartis International AG (Sandoz International GmBH)
6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance
6.3.6. Key strategic moves and developments
6.4. Pfizer Inc. (Hospira)
6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance
6.4.6. Key strategic moves and developments
6.5. STADA Arzneimittel
6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Business performance
6.6. Beijing SL Pharmaceutical Co., Ltd.
6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.7. Fosun Pharmaceutical (Shanghai Fosun Pharmaceutical Co., Ltd.)
6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance
6.7.6. Key strategic moves and developments
6.8. Amgen Inc.
6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance
6.8.6. Key strategic moves and developments
6.9. AstraZeneca Plc
6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product Portfolio
6.9.5. Business performance
6.10. Teva Pharmaceutical Industries Ltd.
6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance
LIST OF TABLES
TABLE 01. ASEAN BIOSIMILARS MARKET, BY COUNTRY, 20172025 ($MILLION)
TABLE 02. OFF GOING PATENTS 2013-2016
TABLE 03. ASEAN BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 04. CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 05. ASEAN AND CHINA BIOSIMILARS MARKET, BY MOLECULE TYPE, 20172025 ($MILLION)
TABLE 06. BIOSIMILARS MARKET FOR HUMAN GROWTH HORMONE, BY REGION, 20172025 ($MILLION)
TABLE 07. BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 20172025 ($MILLION)
TABLE 08. MONOCLONAL ANTIBODIES FROM COMPANEIS IN CHINA
TABLE 09. BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 20172025 ($MILLION)
TABLE 10. PREVALENCE OF DIABETES IN CHINA AND ASEAN COUNTRIES
TABLE 11. BIOSIMILARS MARKET FOR INSULIN, BY REGION, 20172025 ($MILLION)
TABLE 12. BIOSIMILARS MARKET FOR INTERFERON, BY REGION, 20172025 ($MILLION)
TABLE 13. BIOSIMILARS MARKET FOR GRANULOCYTE-COLONY STIMULATING FACTOR, BY REGION, 20172025 ($MILLION)
TABLE 14. BIOSIMILARS MARKET FOR PEPTIDE, BY REGION, 20172025 ($MILLION)
TABLE 15. ASEAN BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 16. CHINA BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 17. ASEAN AND CHINA BIOSIMILARS MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 18. BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 20172025 ($MILLION)
TABLE 19. BIOSIMILARS MARKET FOR ONCOLOGY DISEASES, BY REGION, 20172025 ($MILLION)
TABLE 20. BIOSIMILARS MARKET FOR CHRONIC AND AUTOIMMUNE DISEASES, BY REGION, 20172025 ($MILLION)
TABLE 21. BIOSIMILARS MARKET FOR RHEUMATOID ARTHRITIS (RA), BY REGION, 20172025 ($MILLION)
TABLE 22. BIOSIMILARS MARKET FOR DIABETES, BY REGION, 20172025 ($MILLION)
TABLE 23. BIOSIMILARS MARKET FOR GLAUCOMA, BY REGION, 20172025 ($MILLION)
TABLE 24. BIOSIMILARS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 25. BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 20172025 ($MILLION)
TABLE 26. BIOSIMILARS MARKET FOR OTHERS, BY REGION, 20172025 ($MILLION)
TABLE 27. 3SBIO: COMPANY SNAPSHOT
TABLE 28. 3SBIO: APPLICATION PORTFOLIO
TABLE 29. QILU: COMPANY SNAPSHOT
TABLE 30. SANDOZ: COMPANY SNAPSHOT
TABLE 31. NOVARTIS: OPERATING SEGMENTS
TABLE 32. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 33. PFIZER: COMPANY SNAPSHOT
TABLE 34. PFIZER: OPERATING SEGMENTS
TABLE 35. PFIZER: PRODUCT PORTFOLIO
TABLE 36. STADA: COMPANY SNAPSHOT
TABLE 37. STADA: OPERATING SEGMENTS
TABLE 38. STADA: PRODUCT PORTFOLIO
TABLE 39. BEIJING SL: COMPANY SNAPSHOT
TABLE 40. BEIJING SL: OPERATING SEGMENTS
TABLE 41. BEIJING SL: PRODUCT PORTFOLIO
TABLE 42. FOSUN PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 43. FOSUN PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 44. FOSUN PHARMACEUTICAL: PIPELINE PRODUCT PORTFOLIO
TABLE 45. AMGEN: COMPANY SNAPSHOT
TABLE 46. AMGEN: PRODUCT PORTFOLIO
TABLE 47. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 48. ASTRAZENECA: OPERATING SEGMENTS
TABLE 49. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 50. TEVA: COMPANY SNAPSHOT
TABLE 51. TEVA: OPERATING SEGMENTS
TABLE 52. TEVA: PIPELINE PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ASEAN AND CHINA MARKET SEGMENTATION
FIGURE 02. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 03. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 04. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. LOW THREAT OF SUBSTITUTION
FIGURE 08. MODERATE THREAT OF NEW ENTRANT
FIGURE 09. MODERATE COMPETITIVE RIVALRY
FIGURE 10. ASEAN BIOSIMILARS MARKET, 20172025 ($MILLION)
FIGURE 11. CHINA BIOSIMILARS MARKET, 20172025 ($MILLION)
FIGURE 12. ASEAN AND CHINA BIOSIMILARS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13. 3SBIO, 20152017 ($MILLION)
FIGURE 14. NOVARTIS: NET SALES, 20152017 ($MILLION)
FIGURE 15. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 16. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 17. PFIZER: NET SALES, 20152017 ($MILLION)
FIGURE 18. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 19. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 20. STADA: NET SALES, 20152017 ($MILLION)
FIGURE 21. STADA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 22. STADA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 23. FOSUN PHARMACEUTICAL: NET SALES, 20152017 ($MILLION)
FIGURE 24. FOSUN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 25. FOSUN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 26. AMGEN: NET SALES, 20152017 ($MILLION)
FIGURE 27. AMGEN: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 28. AMGEN: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 29. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. TEVA: NET SALES, 20152017 ($MILLION)
FIGURE 32. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
